Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
MHLW Panel Confirms Positive Cost-Benefit Profile, Efficacy for 9-Valent HPV Vaccine for NIP Inclusion
A Japanese health ministry panel on March 4 agreed that there is no problem with the inclusion of MSD’s nine-valent HPV vaccine Silgard 9 into the national immunization program (NIP) from the standpoint of cost-effectiveness and efficacy. The vaccine evaluation…
To read the full story
Related Article
- Silgard 9 Now Available under NIP; MSD Renews Call for Cervical Cancer Prevention
April 4, 2023
- Silgard 9 Approved for 2-Dose Schedule: MSD
March 9, 2023
- Japan Panel OKs 2-Dose Regimen for Silgard 9 for Girls below Age 15
March 8, 2023
- 9-Valent HPV Vaccine Program to Start in April, Panel Seeks Early Approval of 2-Dose Regimen
November 9, 2022
- Japan Panel OKs Inclusion of Silgard 9 into National Immunization Program
October 5, 2022
- MHLW Panel Members Support Silgard 9 HPV Vaccination for Ages 9-14
August 5, 2022
- MSD Developing 2-Dose Regimen for 9-Valent HPV Vaccine: Panel
April 22, 2021
- MSD’s 9-Valent HPV Vaccine Now Available in Japan
February 25, 2021
- MHLW Panel to Vet Addition of 9-Valent HPV Vaccine into National Program
August 19, 2020
- Japan Approves MSD’s 9-Valent HPV Vaccine 5 Years after Filing
July 21, 2020
REGULATORY
- LDP Panel Chief Calls for Earlier CGP Coverage in Cancer Care
September 4, 2026
- Japan to Revisit Handling of Steroid Creams under OTC-Like Drug Charge
September 4, 2026
- UK Halts Tavneos for New Patients, Approval Revocation Set for March
September 4, 2026
- Japan Picks 5 COVID Vaccines for NIP Use from October
September 3, 2026
- New MHLW Pharma Chief Puts AI in Regulatory Reviews High on Agenda
September 3, 2026
Japan has entered a third straight year of wage hikes averaging 5%, but the pharmaceutical industry is struggling to keep…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…